A 3mg/kg starting dose of infliximab in active spondyloarthritis resistant to conventional treatments is efficient, safe and lowers costs

Joint Bone Spine

Volumn 78, Issue 1, 2011, Pages 50-55

  Tenga, Ginette ^a   Goëb, Vincent ^b   Lequerré, Thierry ^b   Bacquet Deschryver, Hélène ^b   Daragon, Alain ^b   Pouplin, Sophie ^b   Lanfant Weybel, Karine ^b   Le Loët, Xavier ^b   Dieu, Bernard ^a   Vittecoq, Olivier ^b  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

Author keywords

Ankylosing spondylitis; Efficacy; Infliximab; Psoriatic arthritis

Indexed keywords

INFLIXIMAB; ANTIRHEUMATIC AGENT; MONOCLONAL ANTIBODY;

ADULT; AGED; ANKYLOSING SPONDYLITIS; ARTICLE; BLOOD PRESSURE; CHEST TIGHTNESS; CHILL; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISABILITY; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EPIGASTRIC PAIN; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; LARYNX EDEMA; MALAISE; MALE; PALLOR; PSORIATIC ARTHRITIS; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; URTICARIA; VISUAL ANALOG SCALE; COST CONTROL; DRUG RESISTANCE; ECONOMICS; MIDDLE AGED; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, PSORIATIC; COST SAVINGS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SPONDYLITIS, ANKYLOSING; TREATMENT OUTCOME; YOUNG ADULT;

EID: 78651093827     PISSN: 1297319X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jbspin.2010.04.017     Document Type: Article

References (26)

1. Dougados M., van der Linden S., Juhlin R., et al. The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. Arthritis Rheum 1991, 74:1218-1227.
2. Saraux A., Guillemin F., Guggenbuhl P., et al. Prevalence of spondyloarthropathies in France: 2001. Ann Rheum Dis 2005, 64:1431-1435.
3. Anderson J.J., Baron G., van der Heijde D., et al. Ankylosing spondylitis assessment group preliminary definition of short-term improvement in ankylosing spondylitis. Arthritis Rheum 2001, 44:1876-1886.
4. van der Linden S., Valkenburg H.A., Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 1984, 27:361-368.
5. Braun J., Pham T., Sieper J., et al. International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 2003, 62:817-824.
6. Maini R., St Clair E.W., Breedveld F., et al. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. Lancet 1999, 354:1932-1939.
7. Targan S.R., Hanauer S.B., van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 1997, 337:1029-1035.
8. Brandt J., Haibel H., Reddig J., et al. Successful short term treatment of severe undifferentiated spondyloarthropathy with the anti-tumor necrosis factor-alpha monoclonal antibody infliximab. J Rheumatol 2002, 29:118-122.
9. Brandt J., Haibel H., Cornely D., et al. Successful treatment of active ankylosing spondylitis with the anti-tumor necrosis factor alpha monoclonal antibody infliximab. Arthritis Rheum 2000, 43:1346-1352.
10. Ko J.M., Gottlieb A.B., Kerbleski J.F. Induction and exacerbation of psoriasis with TNF-blockade therapy: a review and analysis of 127 cases. J Dermatolog Treat 2009, 20:100-108.
11. Grinblat B., Scheinberg M. The enigmatic development of psoriasis and psoriasiform lesions during anti-TNF therapy: a review. Semin Arthritis Rheum 2008, 37:251-255.
12. Lequerre T., Vittecoq O., Klemmer N., et al. Management of infusion reactions to infliximab in patients with rheumatoid arthritis or spondyloarthritis: experience from an immunotherapy unit of rheumatology. J Rheumatol 2006, 33:1307-1314.
13. Husted J.A., Gladman D.D., Farewell V.T., et al. Health-related quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45:151-158.
14. van der Heijde D., Dijkmans B., Geusens P., et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 2005, 52:582-591.
15. Antoni C., Krueger G.G., de Vlam K., et al. Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150-1157.
16. Brandt J., Khariouzov A., Listing J., et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum 2003, 48:1667-1675.
17. van der Heijde D., Kivitz A., Schiff M.H., et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006, 54:2136-2146.
18. Maksymowych W.P., Jhangri G.S., Lambert R.G., et al. Infliximab in ankylosing spondylitis: a prospective observational inception cohort analysis of efficacy and safety. J Rheumatol 2002, 29:959-965.
19. Jois R.N., Leeder J., Gibb A., et al. Low-dose infliximab treatment for ankylosing spondylitis--clinically- and cost-effective. Rheumatology (Oxford) 2006, 45:1566-1569.
20. Mease P.J., Goffe B.S., Metz J., et al. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial. Lancet 2000, 356:385-390.
21. Antoni C.E., Kavanaugh A., Kirkham B., et al. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). Arthritis Rheum 2005, 52:1227-1236.
22. Kroesen S., Widmer A.F., Tyndall A., et al. Serious bacterial infections in patients with rheumatoid arthritis under anti-TNF-alpha therapy. Rheumatology (Oxford) 2003, 42:617-621.
23. Gomez-Reino J.J., Carmona L., Valverde V.R., et al. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report. Arthritis Rheum 2003, 48:2122-2127.
24. Wolfe F., Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004, 50:1740-1751.
25. Bongartz T., Sutton A.J., Sweeting M.J., et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006, 295:2275-2285.
26. Baeten D., Kruithof E., Van den Bosch F., et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease?. Ann Rheum Dis 2003, 62:829-834.